Latest Ratios: P/E Ratio -25.0x · EV/EBITDA N/A · ROE -61.0%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $399M | $217M | $209M | $202M | $398M | — | — |
| Enterprise Value | $1.2B | $397M | $216M | $209M | $201M | $429M | — | — |
| P/E Ratio → | -24.96 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 13.83 | 5.17 | 3.46 | 2.47 | 1.91 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | 5.70 | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -61.0% | -61.0% | -43.2% | -30.7% | -95.3% | — | — | — |
| ROA | -44.2% | -44.2% | -32.8% | -25.6% | -41.6% | -57.3% | -21.0% | -26.8% |
| ROIC | -46.5% | -46.5% | -36.9% | 28.2% | -47.7% | -79.9% | -49.7% | — |
| ROCE | -48.7% | -48.7% | -40.5% | 33.0% | -41.8% | -31.1% | -22.8% | -26.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | 0.20 | 0.16 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | — | 0.36 | — | — | — | — |
| Net Debt / Equity | — | -0.03 | -0.02 | 0.01 | -0.01 | — | — | — |
| Net Debt / EBITDA | — | — | — | 0.02 | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -100.93 | -100.93 | -91.28 | -746.21 | -19.06 | -1.05 | -42.60 | — |
Net cash position: cash ($16M) exceeds total debt ($14M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.45 | 7.45 | 7.40 | 12.07 | 24.55 | 7.41 | 22.73 | 22.11 |
| Quick Ratio | 7.45 | 7.45 | 7.40 | 12.08 | 24.55 | 9.26 | 22.73 | 21.27 |
| Cash Ratio | 7.32 | 7.32 | 6.87 | 11.52 | 24.10 | 7.11 | 22.04 | 20.85 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $81M | $70M | $69M | $64M | $41M | $40M | $68M |
Clinical Trial Funding Runway
Based on reported financial statements, the company trades at a price-to-book ratio of 11.37, which suggests that market participants are pricing in significant intangible value related to the proprietary Alpha DaRT technology rather than current tangible assets or any near-term earnings potential for the firm.
The elevated P/B multiple relative to broader healthcare peers indicates that investors are essentially buying an option on the successful commercialization of the company's alpha-emitter diffusion platform. Given the absence of revenue, traditional valuation metrics like P/E or EV/EBITDA are non-meaningful, forcing analysts to rely on the implied probability of clinical success and the eventual size of the addressable oncology market.
According to recent quarterly filings, the company's ROIC has consistently trended in negative territory, reaching -11.6% in 2025Q4, which underscores the reality that invested capital is currently being consumed by clinical trial execution rather than generating any productive economic returns for shareholders.
The persistent decay in ROIC is a structural feature of the pre-revenue biotechnology model where capital is deployed into long-gestation R&D projects. Investors should monitor whether the company can eventually pivot toward positive returns once the regulatory hurdles for its lead indications are cleared and commercial manufacturing scales.
As reported in the latest balance sheet data, the current ratio has compressed to 7.45 in 2025Q4 from a peak of 14.66 in 2023Q3, signaling that the company's liquidity position is tightening as it aggressively funds its multi-center pivotal clinical trials and specialized isotope infrastructure.
While a current ratio of 7.45 appears robust in isolation, it masks the reality of a high quarterly cash burn rate that threatens to exhaust the $15.9M cash balance in the near term. This rapid consumption of liquid assets warrants further investigation into the timing of potential future equity raises or strategic partnerships.
Based on an analysis of the company's business model, the current ratio is the most commonly misapplied metric, as it fails to account for the unique 'half-life' risk of radioactive inventory and the non-cash nature of warrant liabilities that frequently distort the firm's true working capital.
Relying on standard liquidity ratios obscures the fact that a significant portion of current assets may be tied up in specialized, short-lived radioactive materials that cannot be easily liquidated. Analysts should instead focus on the 'cash-to-milestone' runway, which provides a more accurate assessment of the company's ability to survive until the next critical clinical data readout.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DRTS stock.
Alpha Tau Medical Ltd.'s current P/E ratio is -25.0x. This places it at the 50th percentile of its historical range.
Alpha Tau Medical Ltd.'s return on equity (ROE) is -61.0%. The historical average is -57.5%.
Based on historical data, Alpha Tau Medical Ltd. is trading at a P/E of -25.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.